References
- 1. Alshareef A, Gupta N, Zhang HF, Wu C, Haque M, Lai R. High expression of β-catenin contributes to the crizotinib resistant phenotype in the stem-likecell population in neuroblastoma. Sci Rep. 2017 Dec 4;7(1):16863. doi: 10.1038/s41598-017-17319-9.
- 2. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res. 2010;16(17):4353-62.
- 3. Tucker ER, Tall JR, Danielson LS, Gowan S, Jamin Y, Robinson SP, Banerji U, Chesler L. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Mol Oncol. 2017 Aug;11(8):996-1006. doi: 10.1002/1878-0261.12069. Epub 2017 May 31.
- 4. Carpenter EL, Mossé YP. Targeting ALK in neuroblastoma- preclinical and clinical advancements. Nat Rev Clin Oncol. 2012 May 15;9(7):391-9. doi: 10.1038/nrclinonc.2012.72.
- 5. Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALKmutated neuroblastoma.Oncotarget. 2014 Sep 30;5(18):8737-49.
- 6. Duijkers FA, Gaal J, Meijerink JP, Admiraal P, Pieters R, de Krijger RR, van Noesel MM. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. Am J Pathol. 2012;180(3):1223-3
- 7. Murga-Zamalloa C, Lim MS.ALK-driven tumors and targeted therapy: focus on crizotinib. Pharmgenomics Pers Med. 2014 Mar 20;7:87-94. doi: 10.2147/PGPM.S37504. eCollection 2014.